Because we have found that inhibiting the CD95-mediated Ca2+ response does not interfere with apoptotic signaling, we propose that selective blockade of CD95-mediated Ca2+ signaling might open new therapeutic avenues for SLE treatment in the future. This evidence concerns the gene FAS and systemic lupus erythematosus.